Thermo Fisher Scientific CD38 Monoclonal Antibody (38.H1)

Applications and Tested Dilution

Product Specifications

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.

CD38 glycoprotein is a particularly attractive target on malignant plasma cells at all stages of disease and in Chronic Lymphocytic Leukemia (CLL) patients with poor clinical prognosis. It is highly expressed in lymphoid tumors including multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferation. In contrast, the molecule is detectable only at very low levels in mature lymphocytes or in nonhematopoietic tissues.

Therapeutic Anti-CD38 antibodies (e.g., Daratumumab) can induce strong antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity to kill tumors. GenScript Human CD38 Antibody (38.H1), mAb, Mouse is produced from a hybridoma resulting from the fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with recombinant human CD38.

Target Information

CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein that induces activation, proliferation, and differentiation of mature lymphocytes and mediates apoptosis of myeloid and lymphoid progenitor cells.

CD38 functions as a multi-catalytic ectoenzyme serving as ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase, and possibly NAD+ glycohydrolase or as a cell surface receptor.

Antibodies to CD38 are useful in:

• Subtyping of lymphomas and leukemias
• Detection of plasma cells (identification of myelomas)
• Marker for activated B and T cells

CD38 participates in cell adhesion, signal transduction, and calcium signaling. It is expressed at high levels in the pancreas, liver, kidney, malignant lymphoma, and neuroblastoma. Diseases associated with CD38 dysfunction include chronic lymphocytic leukemia and Richter’s Syndrome.

For Research Use Only.
Not for use in diagnostic procedures.
Not for resale without express authorization.